Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

Abstract Background PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated...

Full description

Bibliographic Details
Main Authors: Patricia Martin‐Romano, Eduardo Castanon, Samy Ammari, Stéphane Champiat, Antoine Hollebecque, Sophie Postel‐Vinay, Capucine Baldini, Andrea Varga, Jean Marie Michot, Perrine Vuagnat, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté, Christophe Massard
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Cancer Medicine
Subjects:
Immune checkpoint inhibitor
pseudoprogression
response evaluation criteria in solid tumors
treatment beyond progression
Online Access:https://doi.org/10.1002/cam4.2797

Internet

https://doi.org/10.1002/cam4.2797

Similar Items